The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

Provided in the present invention are a compound and application thereof. The compound of the present invention has a structure as shown in the formula (1). The compound obtained in the present invention by connecting phenanthrene and fluoranthene groups via nitrogen has the advantages of great optical, electrical, and thermal stability, high luminescence efficiency, low electric voltage, and long service life, and can be used in organic electroluminescent devices. In particular, the compound has the potential for application in the AMOLED industry as an electron blocking layer material or a hole transport layer material.

##STR00001##

The present specification relates to a compound represented by Chemical Formula 1, and an organic light emitting device including the same.

The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan characteristics can be provided.

The present invention relates to the use of compounds for structuring of at least one functional layer of an organic electronic device. The present invention further relates to preferred compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.

A cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series in a synthesizer, includes: at least one manifold provided with a plurality of valves connectable to and operable by the synthesizer; an anion-exchanger comprising an anionic exchange material; an eluent container comprising an eluent; and a recondition container comprising a reconditioning agent.

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

An organic electroluminescence device comprising: a cathode, an anode, and an organic layer disposed between the cathode and the anode, wherein the organic layer comprises a compound represented by the following formula (1), and a compound A having a Stokes shift of 20 nm or smaller and an emission peak wavelength of 440 nm to 465 nm (at least one of Ar.sub.1 and Ar.sub.2 is a monovalent group having a structure represented by the following formula (2)).

##STR00001##

A compound represented by the following formula (1), wherein in the formula, L.sub.1 and L.sub.2 are predetermined linking groups, and Ar.sub.1 is a monovalent group having a structure represented by the following formula (2).

##STR00001##